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Abstract
Haspin is a serine/threonine kinase that phosphorylates Thr-3 of histone H3 in mitosis that has
emerged as a possible cancer therapeutic target. High throughput screening of approximately
140,000 compounds identified the beta-carbolines harmine and harmol as moderately potent
haspin kinase inhibitors. Based on information obtained from a structure-activity relationship
study previously conducted for an acridine series of haspin inhibitors in conjunction with in silico
docking using a recently disclosed crystal structure of the kinase, harmine analogs were designed
that resulted in significantly increased haspin kinase inhibitory potency. The harmine derivatives
also demonstrated less activity towards DYRK2 compared to the acridine series. In vitro mouse
liver microsome stability and kinase profiling of a representative member of the harmine series
(42, LDN-211898) are also presented.
The serine/threonine kinase haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase,
also known as Germ Cell Specific Gene-2; Gsg2)1 functions in mitosis, where it
phosphorylates histone H3 at Thr-3 (H3T3ph).2 During mitosis, this phosphorylation
generates a binding site on H3 for Survivin and thereby positions the Chromosome
Passenger Complex at centromeres to regulate chromosome segregation,3, 4 and it also
displaces proteins such as TFIID that normally bind to H3 through methylated Lys-4.5
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Depletion of haspin by RNA interference, or microinjection of H3T3ph antibodies, causes
chromosome alignment defects and failure of normal mitosis.2, 3, 6
Human haspin has ATP-binding and catalytic sites structurally similar to other members of
the eukaryotic protein kinase (ePK) superfamily with several notable exceptions. For
example, the highly conserved DFG motif involved in ATP binding and the APE motif
involved in stabilizing the C-terminal lobe among ePKs are altered or absent and the
activation loop region is substantially rearranged in haspin compared to other ePKs.7, 8
Haspin kinase inhibitors are expected to be useful probes for elucidating the cellular roles of
this protein and may have therapeutic utility in treating cancer. A recently described small
molecule, CHR-6494 (1), that inhibits haspin displayed anti-tumor activity in a mouse
xenograft model.9 Also, 5-iodotubercidin (2) has been reported as an effective haspin kinase
inhibitor.7, 10
We previously utilized a time-resolved fluorescence resonance energy transfer (TR-FRET)
high throughput screening (HTS) assay to identify the acridine derivative 3 (LDN-192960)
as another potent haspin inhibitor (Figure 1; IC50 = 0.010 µM).11, 12 This assay has now also
been used to discover the beta-carbolines harmine, 4, and harmol, 5, as moderately potent
haspin inhibitors with IC50 values of 0.59 and 0.77 µM, respectively. Harmine has
previously been identified as an inhibitor of DYRK family kinases, with IC50 values
between 0.03 and 0.35 µM reported for DYRK1A, and approximately 50-fold lower potency
toward DYRK2.13 Herein, we describe the design, synthesis and improved potency of the
beta-carboline series for haspin inhibition utilizing the structure-activity relationships
previously determined for the acridine series12 combined with in silico docking using a
recently disclosed crystal structure of the kinase.7 In addition, in vitro mouse liver
microsome stability and kinase profiling of a representative beta-carboline analog are
presented.
A crystal structure of haspin bound to AMP was used for docking calculation.7, 14 Analysis
of this structure revealed key hydrogen bonds between nitrogen atoms of the adenine ring of
AMP and protein backbone atoms of residues E606 and G608 (Figure S1).15 A 12Å docking
grid was generated using the AMP center of mass as the point of origin with a single
hydrogen bond constraint on the backbone amide of G608. Docking calculations were
performed on 3, which demonstrated that this inhibitor was well accommodated within the
binding site and satisfied the hydrogen bonding constraint on G608 (Figure 2). In addition,
the inhibitor also made a hydrogen bond with K511, which likely disrupts a key salt bridge
between this residue and E535 that is necessary for closure of the ATP-binding cleft
enabling kinase activity. A metadynamic simulation sampling the two torsion angles (Χ1 and
Χ2) of the alkylamine as collective variables was also conducted. One low energy
conformation was found (Figure S2) that allowed a hydrogen bond between the amine and
D611 (Figure 2).
Next, docking calculations were performed on four harmine analogs (7a – b and 9a – b) that
incorporate at two different positions alkylamines similar to that present in 3. The two
derivatives with the alkylamine on the N9-position (9a and 9b) were well accommodated
within the binding site making a hydrogen bond with D687 as well as the hydrogen bonding
constraint on G608 (Figure 3B and C). In contrast, compounds 7a and 7b resulted in steric
hindrance with the region around F607 and G608 and were not well situated within the
ATP-binding site, suggesting that they would unlikely be haspin inhibitors. A similar
metadynamic simulation for 9a sampling two torsion angles (Χ1 and Χ2) of the alkylamine
as collective variables found two low energy conformations (Figure 3A). One of these
allowed a hydrogen bond between the amine and D611 (Figure 3B), similar to 3. However,
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the second conformation permitted a hydrogen bond between the amine and the backbone
carbonyl of I490 in the glycine-rich loop (Figure 3C).
The initial beta-carboline derivatives used in the in silico docking experiments were
prepared using the procedure outlined in Scheme 1. Harmol, 5, was O-alkylated with N-
Boc-protected alkylamines in the presence of cesium carbonate to give 6a and 6b. The
carbamate protecting group was removed under acidic conditions to give 7a and 7b.
Harmine, 4, could be N-alkylated. However, phthalimide-protected alkylamines were
required and a stronger base (i.e. NaH) was also needed to give 8a and 8b. Removal of the
protecting group was accomplished using hydrazine hydrate to yield 9a and 9b.
Haspin kinase inhibitory activity for the various compounds was assessed using the same
assay utilized for the HTS, except in the presence of varying concentrations of test
compounds.11, 15 As anticipated 7a and 7b were inactive haspin inhibitors at 10 µM.
However, 9a and 9b were both active demonstrating IC50 values of 0.46 and 0.17 µM,
respectively (Table 1).
Based on these results additional beta-carboline analogs were prepared using the general
procedure outlined in Scheme 2. Indoles 10 were either directly converted to derivative 11
using Me2NCH=CHNO2 (generated from MeNO2 and Me2NCH(OMe)2 at 85 °C for 0.5 h)
or in a two step procedure (i.e. Vilsmeier-Haak followed by Henry reactions). The alkene
and nitro groups were both reduced in the presence of lithium aluminum hydride (LAH) to
give 12. A Pictet-Spengler reaction between 12 and various aldehydes generated 11. In the
case where R1 = CF3, the hemiacetal CF3CHOH(OEt) was used. Oxidation of the
tetrahydro-beta-carboline with manganese dioxide gave 14. Finally as previous outlined,
alkylation generated 15, which was de-protected to give 16.
Several other beta-carboline derivatives were also prepared using the procedures outlined in
Scheme 3. Intermediate 17 was de-methylated using HBr in acetic acid to give phenol 18.
This material was converted to triflate 17 and then a methylsulfonamide was introduced
utilizing a Pd-catalyzed reaction to yield 20. Removal of the protecting group gave amine
21. Likewise, intermediate 16 was converted to the t-butyl ether 22 in the presence of
Me2NCH(O-t-Bu)2, which was again de-protected to liberate amine 23. Intermediate 17 was
also de-protected to give 24, which was converted to the tertiary amine 25 through reductive
amination. Finally, intermediate 24 was converted to the secondary amine 27 via the
formamide 26.
The additional compounds prepared were used to further explore the structure-activity
relationship of 9b for haspin inhibition (Table 1). Removal of the methyl at the 1-position
(28) or replacement with an isopropyl (29) were detrimental, where as replacement with an
ethyl (30) was equivalent. Replacing the methoxy in the 7-position with a hydroxyl (31) was
tolerated, but a fluorine (32), methyl sulfonamide (33) or t-butoxy (34) were detrimental.
Transposition of the methoxy to the 5- or 6-positions (35 and 36) resulted in loss of activity,
while introduction of the methoxy to the 8-position (37) was more tolerated. The 6,7- and
7,8-disubstituted analogs 38 and 39 demonstrated less activity. The primary amine also
appeared to be optimal, where the secondary (40) and tertiary (41) amines were less active.
Finally, in order to potentially improve metabolic stability analogs (42 and 43) that replace
the methyl group in the 1-position with a trifluoromethyl were evaluated. Gratifyingly, 42
displayed an IC50 value of 100 nM for inhibiting haspin. This compound was also assessed
for in vitro metabolic stability in pooled mouse liver microsomes and demonstrated
excellent stability with a t1/2 of 341 min and a CLint of 3.8 µL/min/mg protein suggesting
that this compound may be useful as an in vivo probe.15, 16
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The beta-carboline series was also evaluated for inhibition of human DYRK2 using a
previously described assay.12 Harmine and harmol gave IC50 values for DYRK2 inhibition
of 0.69 and 1.5 µM, consistent with previous studies.13 Introduction of the tethered amine
onto the N9-position substantially reduced the potency for DYRK2 inhibition in all cases
examined (Table 1). For example, 42 had an IC50 value for DYRK2 of 15 µM and
demonstrated 150-fold selectivity for haspin over DYRK2.
Lastly, haspin inhibitor 42 was assessed against a panel of 292 kinases at 10 µM. At this
high concentration, the compound inhibited thirteen kinases, in addition to haspin, ≥
90%.15, 17 These kinases were CaMK2b, CaMK2d, CDK7-CycH-Mat1, cGK2, CK1d,
CLK1, CLK2, DYRK1A, DYRK1B, DYRK3, PASK, PIM1 and PKD3. Interestingly, many
of these enzymes belong to the CMGC group of kinases, unlike haspin which is a divergent
member of the ePK family.18 In addition, a comparison of the profiles of 3 and 42 suggested
that only six kinases, including haspin, were inhibited by both compounds ≥ 90% at 10 µM
(Figure 4).12 Profiling of additional haspin kinase inhibitors, such as 1 and 2, may further
reduce the number of kinases, besides haspin, which are known to be potently inhibited by
all the compounds. In addition, the collective use of 3, 42 and potentially other haspin
inhibitors in cell based assays may allow for more concrete conclusions to be reached with
regard to haspin’s biological functions.
In conclusion, a structure-activity relationship study of the beta-carbolines 4 and 5,
identified utilizing a recently developed HTS assay for haspin kinase inhibitory activity, was
performed guided by insights obtained from a previously optimized compound series12
combined with in silico docking and metadynamic calculations. Increased potency was
accomplished by introduction of a tethered primary amine onto the N9-position of the beta-
carboline. Potency was further increased by replacing the methyl at the 1-position with a
trifluoromethyl giving 42. In addition, this analog demonstrated excellent in vitro metabolic
stability in pooled mouse liver microsomes. Kinase profiling of 42 suggested that it was
fairly selective and inhibited only six kinases (≥ 90% at 10 µM), including haspin, in
common with the previously identified acridine inhibitor 3. The beta-carboline haspin
inhibitor 42 (LDN-211898) described herein, along with other structurally distinct inhibitors
such as 1 – 3 provide valuable molecular probes to study the cellular functions of haspin
kinase and may have potential therapeutic utility in treating cancer.
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Figure 1.
Haspin inhibitors identified by radiometric, thermal stability shift and TR-FRET HTS
assays.
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Figure 2.
Molecular docking of 3 at the ATP-binding site of haspin. Χ1 and Χ2 are the torsion angles
that were sampled during the metadynamic calculation.
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Figure 3.
(A) Free energy surface map from metadynamic calculations sampling two torsion angles
(Χ1 and Χ2) of 9a. Blue and red represent low and high energy conformations, respectively.
(B and C) Docking of 9a at the ATP-binding site of haspin for the two conformations of the
alkylamine side-chain based on metadynamic calculations.
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Figure 4.
A Venn diagram highlights kinases selectively inhibited by 3 (red) or 42 (blue) by ≥ 90% at
10 µM. The overlapping region contains only six kinases inhibited by both compounds.
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Scheme 1.
Reagents and conditions: (a) Br(CH2)nNHBoc, Cs2CO3, DMF, rt; (b) HCl, MeOH, rt; (c)
Br(CH2)nNPhth, NaH, DMF, rt; (d) NH2NH2•H2O, EtOH, 65 °C. Phth = phthalimide.
Cuny et al. Page 10
Bioorg Med Chem Lett. Author manuscript; available in PMC 2013 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Scheme 2.
(a) Me2NCH=CHNO2, TFA, rt, 30 min; (b) POCl3, DMF, 0 °C to rt then MeNO2, NH4OAc,
100 °C, 1 h; (c) LiAlH4, THF, rt; (d) R1CHO or CF3CHOH(OEt), MeOH, cat. HCl, rt; (e)
MnO2, 5% Pd/C, DMF, microwave (MW), 150 °C; (f) Br(CH2)nNPhth, NaH, DMF, rt; (g)
NH2NH2•H2O, MeOH, DCM.
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Scheme 3.
(a) HBr, AcOH, MW, 130 °C; (b) Tf2O, i-Pr2EtN, DCM, 0 °C to rt; (c) MeSO2NH2,
Pd2(dba)3, xPhOS, K3PO4, toluene, 110 °C, 1 h; (d) NH2NH2•H2O, MeOH, DCM; (e)
Me2NCH(O-t-Bu)2, DMF, 120 °C, 1 h; (f) CH2O, HCO2H, MW, 150 °C; (g) EtOCHO,
MW, 160 °C; (h) LiAlH4, THF, rt.
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